Search clinical trials for: OXi4503

Total 4 results

Mateon Therapeutics
Cancer Research UK

Completed

Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors

Solid Tumors

United Kingdom
Mateon Therapeutics

Unknown

Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS (AML)

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

United States
University of Florida
The Leukemia and Lymphoma Society

Terminated

A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS

Myelodysplastic Syndromes | Leukemia, Myelogenous, Acute

United States
Mateon Therapeutics

Completed

Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden (OXi4503)

Neoplasm Metastasis

Australia

3

Subscribe